AbbVie is hoping for accelerated approval of antibody-drug conjugate after positive PhII datanews2023-11-29T20:03:43+00:00November 29th, 2023|Endpoints News|
Gilead’s cell therapy business Kite cuts 7% of workforcenews2023-11-29T19:48:23+00:00November 29th, 2023|Endpoints News|
Boehringer Ingelheim and IBM team up to make antibodies with generative AInews2023-11-29T19:29:15+00:00November 29th, 2023|Endpoints News|
Health insurance giants Cigna and Humana reportedly in talks to mergenews2023-11-29T18:09:35+00:00November 29th, 2023|Endpoints News|
Intas Pharmaceuticals’ Indian facility hit with FDA warning letter, placed on import alertnews2023-11-29T17:45:30+00:00November 29th, 2023|Endpoints News|
Generation Bio to lay off 68 employees in a difficult year for non-viral gene therapy biotechsnews2023-11-29T16:26:16+00:00November 29th, 2023|Endpoints News|
Arrivo bags $45M Series B to fund major depression late-stage test and PhII-ready pancreatitis assetnews2023-11-29T16:16:58+00:00November 29th, 2023|Endpoints News|
Lilly to pay up to $660M in new deal with PRISM BioLab; Boehringer partners with Phenomic AInews2023-11-29T15:55:08+00:00November 29th, 2023|Endpoints News|
Neuro startup stock craters after PhIII study marred with ‘significant deviation’ from trial protocolnews2023-11-29T15:32:58+00:00November 29th, 2023|Endpoints News|
Verve raises $148M via public stock offering, private placement with Eli Lillynews2023-11-29T12:14:29+00:00November 29th, 2023|Endpoints News|
